Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study Evaluating CMTX-101 for Infections Associated with Cystic Fibrosis

Published By :
June 16, 2025
email icon in blackFacebook icon in blacktwitter icon in blackLinkedIn icon in black
gradient colors in orange, pink and purple

Recent News & Insights

Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study Evaluating CMTX-101 for Infections Associated with Cystic Fibrosis

Featured News
·
June 16, 2025

TeamCentral Raises $3.875M Seed Round to Accelerate Enterprise AI-Readiness and Integration Automation

Featured News
·
May 27, 2025

SOLVE FSHD Announces $3 Million Investment in Armatus Bio to Advance Gene Therapy Program for FSHD

Featured News
·
May 6, 2025
More News And Insights
Subscribe TO our newsletter

Stay Up To Date With Our News & Insights

Stay informed with current news about our portfolio companies, events and industry insights.
email icon in gradient orange, pink and purple colors
You are subscribed to our newsletters
Oops! Something went wrong while submitting the form.
CincyTech is a venture capital firm that invests in innovative founders tackling the world's complex challenges. Our experienced team is fluent in the language of founders, researchers, and inventors working with deep domain expertise and market foresight. We partner early to help transform ideas into world-class companies.
2900 Reading Rd. Ste. 410 Cincinnati, OH 45206
Contact CincyTech
Twitter icon in white
Cincytech logo
HomeApproachPortfolioTeamCommunityNews & InsightsPitch Us
© 2023 Copyright - CincyTech
CareersUniversity ProgramsDisclosures
Made by 5Four Digital®